Generalized Pustular Psoriasis (GPP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

     Generalized pustular psoriasis is an uncommon and severe variant of psoriasis, marked by sudden, painful outbreaks of pus-filled blisters covering extensive body areas. It can also bring general symptoms like fever, headaches, extreme fatigue, and skin-burning sensations. Distinguishing it from the more typical plaque psoriasis is essential. Several factors can trigger or worsen generalized pustular psoriasis, including:

1.       Infections: Viral or bacterial infections often exacerbate the condition.

2.       Medications: Corticosteroids are a significant trigger, but other drugs like ciclosporin, terbinafine, and others have been implicated.

3.       Psychological Stress: Stress can lead to deterioration in some individuals.

4.       Hypocalcemia: Low calcium levels, either from the disease or other causes like hypoparathyroidism, can activate the condition.

5.       Pregnancy: Pregnancy is a recognized risk factor.

In certain populations, genetic mutations in IL36RN have been linked to familial and sporadic cases of generalized pustular psoriasis, with specific mutations varying among populations. Diagnostic laboratory tests include elevated erythrocyte sedimentation rate, C-reactive protein levels, lymphopenia followed by leukocytosis, low plasma albumin, zinc, calcium, and abnormal lipid profiles. The disease may be mistaken for a systemic infection due to fever and elevated inflammatory markers during acute phases, potentially leading to incorrect treatment decisions. Without effective treatment, the acute phase can be life-threatening. Prognosis is generally better when there is a clear trigger, such as pregnancy-related generalized pustular psoriasis. However, cases stemming from acrodermatitis continua of Hallopeau tend to have a worse outlook. Treatment for generalized pustular psoriasis involves various approaches - Conservative Treatment includes - Encouraging adequate fluid and protein intake, Monitoring fluid balance, Addressing any concurrent infections with antibiotics, terminating the pregnancy if maternal life is at risk, and preventing hypothermia. Topical Treatment includes- Applying gentle emollients and Using diluted corticosteroids. Systemic Treatment (in order of preference)- First line- Acitretin (not recommended during pregnancy) at a dose of 1 mg/kg/day, Ciclosporin at 3.5 to 5 mg/kg/day, Methotrexate at 0.2 to 0.4 mg/kg/day. Second line- Infliximab, Adalimumab, Etanercept, Prednisolone (only in specific conditions or complications). Third line - Anakinra.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Generalized Pustular Psoriasis (GPP) – market outlook, epidemiology, competitive landscape, and market forecast report – 2022 to 2032